title: Gray zone lymphoma: better treated like hodgkin lymphoma or mediastinal large B-cell lymphoma?
abstract: Although primary mediastinal large B-cell lymphoma (PMBL) and classic Hodgkin lymphoma of the nodular sclerosis type (CHL-NS) are distinct diseases, they share several clinical characteristics and biologic features. Given that, it is not surprising that there exist mediastinal lymphomas that do not fit well into either category but have clinical and morphologic features overlapping and transitional between PMBL and CHL-NS. The term mediastinal gray zone lymphoma (MGZL) has been used for these tumors, which are included in the World Health Organization classification as "B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classic Hodgkin lymphoma." Although several studies have evaluated different therapeutic strategies in PMBL and CHL-NS, there is a paucity of prospective experience treating MGZL, given its rarity and relatively recent recognition. Historically, diseases that today would be categorized as MGZL were probably called "anaplastic large-cell lymphoma Hodgkin-like," and their outcome with standard approaches was poor, with short overall survivals. In this review-following a discussion of the biology and clinical features of MGZL, and how they compare to PMBL and CHL-NS-we outline how the treatment of PMBL and CHL-NS has evolved in recent years, and how we believe MGZL should be approached therapeutically.
authors: Metabolism Branch, Center for Cancer Research, National Cancer Institute, Rockville Pk, Bethesda, MD 20892, USA.
authors: Kieron
authors: K
authors: Dunleavy
authors: Cliona
authors: C
authors: Grant
authors: Franziska C
authors: FC
authors: Eberle
authors: Stefania
authors: S
authors: Pittaluga
authors: Elaine S
authors: ES
authors: Jaffe
authors: Wyndham H
authors: WH
authors: Wilson
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001761:Bleomycin / Q000627:therapeutic use; D003606:Dacarbazine / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D006689:Hodgkin Disease / Q000145:classification / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000145:classification / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D008466:Mechlorethamine / Q000627:therapeutic use; D008479:Mediastinal Neoplasms / Q000145:classification / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D010641:Phenotype; D011241:Prednisone / Q000627:therapeutic use; D011344:Procarbazine / Q000627:therapeutic use; D014747:Vinblastine / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D001761:Bleomycin; D011344:Procarbazine; D008466:Mechlorethamine; D014750:Vincristine; D014747:Vinblastine; D003606:Dacarbazine; D004317:Doxorubicin; D011241:Prednisone